Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk.
Gut microbiota has been recently established to have a contributory role in the development of cardiometabolic disorders, such as atherosclerosis, obesity, and type 2 diabetes. Growing interest has focused on the modulation of gut microbiota as a therapeutic strategy in cardiovascular diseases and metabolic disorders. In this paper, we have reviewed the impact of gut microbiota on metabolic disorders and cardiovascular disease risk, focusing on the newest findings in this field.
Institute of Internal Medicine, Policlinico Gemelli Hospital, Catholic University of Sacred Heart of Rome, Rome, Italy. luca.miele@rm.unicatt.it.|Clinical Division of Internal Medicine, Gastroenterology and Liver Unit, Complesso Integrato Columbus Hospital, Catholic University of Sacred Heart of Rome, Rome, Italy. luca.miele@rm.unicatt.it.
Luca
L
Miele
Pediatric Department, Policlinico Gemelli Hospital, Catholic University of Sacred Heart of Rome, Rome, Italy. valentina.giorgio@rm.unicatt.it.
Valentina
V
Giorgio
Institute of Internal Medicine, Policlinico Gemelli Hospital, Catholic University of Sacred Heart of Rome, Rome, Italy. mariadele.alberelli@gmail.com.
Maria Adele
MA
Alberelli
Institute of Internal Medicine, Policlinico Gemelli Hospital, Catholic University of Sacred Heart of Rome, Rome, Italy. edecandia@rm.unicatt.it.
Erica
E
De Candia
Institute of Internal Medicine, Policlinico Gemelli Hospital, Catholic University of Sacred Heart of Rome, Rome, Italy. agasbarrini@rm.unicatt.it.
Antonio
A
Gasbarrini
Institute of Internal Medicine, Policlinico Gemelli Hospital, Catholic University of Sacred Heart of Rome, Rome, Italy. agrieco@rm.unicatt.it.
Antonio
A
Grieco
D018407:Bacterial Physiological Phenomena; D002318:Cardiovascular Diseases / Q000382:microbiology* / Q000503:physiopathology / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000382:microbiology* / Q000503:physiopathology / Q000517:prevention & control; D000069196:Gastrointestinal Microbiome; D041981:Gastrointestinal Tract / Q000382:microbiology*; D006801:Humans; D007249:Inflammation / Q000382:microbiology* / Q000503:physiopathology; D007333:Insulin Resistance; D009765:Obesity / Q000382:microbiology* / Q000503:physiopathology / Q000517:prevention & control; D019936:Probiotics / Q000627:therapeutic use
Cardiovascular disease; Gut microbiota; Obesity; Platelets; Type 2 diabetes